CMPX COMPASS THERAPEUTICS INC

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

  • Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET.

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC). 

Webinar Details:

Date: Tuesday, April 1, 2025

Time: 8 AM EDT

Webcast:

Virtual/Replay availability: A replay will be archived for 90 days on Compass’ page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at .

Investor Contact

Media Contact

Anna Gifford, Chief of Staff



617-500-8099



EN
31/03/2025

Underlying

CMPXCOMPASS THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COMPASS THERAPEUTICS INC

 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differe...

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed select competitive antibodies in the class, including ivonescimab, in controlling tumor growth across multiple xenograft and syngeneic models.IND submission is on track for Q4 2025. BOSTON, Nov. 04, 2025 (GLOBE...

33m 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in Upcoming November Investor Even...

Compass Therapeutics to Participate in Upcoming November Investor Events BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November. Details are as follows: Guggenheim 2nd Annual Healthcare Innovation ConferenceLocation: Boston, MADate: Monday, November 10, 2025 Time: 3:30 PM ETWebcast Link: ...

November 3, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in Upcoming September Investor Eve...

Compass Therapeutics to Participate in Upcoming September Investor Events BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September. Details are as follows: Citi’s 2025 Biopharma Back to School Conference Location: Boston, MADate: Tuesday, September 2, 2025 Cantor Global Healthcare ConferenceL...

August 26, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Announces Pricing of Upsized $120 Million Public ...

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2...

August 13, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Announces Proposed Public Offering

Compass Therapeutics Announces Proposed Public Offering BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compas...

August 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch